2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/09/17Chiasma Reports Third Quarter 2017 Results
WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the third quarter ended September 30, 2017. “We are encouraged by the progress we are making toward advancing octreotide capsules as a maintenance treatment for adult acromegaly patients,” said Mark Fitzpatrick, president and CEO of Chiasma. “During the... 
Printer Friendly Version
11/01/17Chiasma Recognizes Acromegaly Awareness Day
WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognized Acromegaly Awareness Day, the patient community and the tremendous work being done to enhance patients’ quality of life. “Through years of partnering with the patient community, we have forged a strong bond with many of those who struggle with this rare and debilitating di... 
Printer Friendly Version
09/27/17Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly
Phase 3 MPOWERED Trial Surpasses 50% Patients Randomized WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided an update on both of its international Phase 3 clinical trials of its octreotide capsules product candidate, conditionally trade-named Mycapssa®, for the maintenance therapy of adult patients with acromegaly.   The c... 
Printer Friendly Version
08/10/17Chiasma Reports Second Quarter 2017 Results
Anticipated release of top-line data from new OPTIMAL trial by end of 2019 WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the second quarter ended June 30, 2017. “We are excited to move forward in our mission of advancing octreotide capsules as a maintenance treatment for adult acromegaly patients,... 
Printer Friendly Version
08/10/17Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
Chiasma plans to initiate enrollment in the new Phase 3 clinical trial – OPTIMAL – during second half of 2017 Anticipates release of top-line data from new OPTIMAL trial by end of 2019 Conference call and webcast scheduled for 5 p.m. ET today WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced it has reached agreement with t... 
Printer Friendly Version
06/19/17Chiasma Appoints Roni Mamluk, Ph.D. to Board of Directors
Longtime Chiasma Executive Also Assumes Director Role with Chiasma, Ltd, its Israeli Subsidiary WALTHAM, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Roni Mamluk, Ph.D., has been re-appointed to Chiasma’s Board of Directors. Recently, she also transitioned from her position as chief development officer to a part-time role a... 
Printer Friendly Version
05/05/17Chiasma Reports First Quarter 2017 Results
WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the first quarter ended March 31, 2017. “We remain in dialogue with the FDA to determine a viable development and regulatory path forward for octreotide capsules as a potential new oral treatment option for adult patients with acromegaly,” said Mark J. F... 
Printer Friendly Version
03/30/17Chiasma Announces Poster Presentation at ENDO 2017 on Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire
WALTHAM, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced a poster presentation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) at ENDO 2017: The Endocrine Society’s 99th Annual Meeting & Expo at 1 p.m. ET on April 2, 2017 at the Orange County Convention Center in Orlando, Florida. The Acro-TSQ is a novel to... 
Printer Friendly Version
03/16/17Chiasma Reports Fourth Quarter and Year End 2016 Results
WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the fourth quarter and year ended December 31, 2016. “Chiasma remains committed to developing a new oral treatment option for patients with acromegaly despite the challenging year that we’ve had,” said Mark J. Fitzpatrick, president and chief executive... 
Printer Friendly Version
03/01/17Chiasma to Present at the Cowen and Company 37th Annual Health Care Conference
WALTHAM, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that its President and Chief Executive Officer, Mark Fitzpatrick, and SVP, Medical and Clinical Affairs, William Ludlam, will present at the Cowen and Company’s 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 8:40 a.m. ET. A live and archived audio webcas... 
Printer Friendly Version
01/09/17Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017
WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate review of 2016 and preliminary outlook for 2017. “2016 was a challenging year for Chiasma due to our receipt of a Complete Response Letter for Mycapssa from the FDA at the time of our PDUFA date in April 2016. Despite this setback, we remain committed to developing new treatmen... 
Printer Friendly Version

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.